Latest news about Kabra Drugs
Kabra Drugs
19.97
-0.52(-2.54%)
Company Performance:
View Company Insights1D-2.54%
1M-20.94%
6M-34.57%
1Y+9.25%
5Y0.00%
More news about Kabra Drugs
21May 26
Kabra Drugs board to meet on May 29 to consider Q4 results
Kabra Drugs Limited announced that its Board of Directors will meet on May 29, 2026, to consider and approve the unaudited financial results for the quarter ended March 31, 2026. The meeting is scheduled to take place at the company's Corporate Office in Chennai. Following regulatory protocols, the trading window for the company's shares has been closed for insiders and will reopen 48 hours after the results are declared.
08May 26
Kabra Drugs Limited Issues Postal Ballot Notice for Name Change to Aanjaay Industries Limited and MOA Object Expansion
Kabra Drugs Limited has issued a postal ballot notice dated May 8, 2026, seeking shareholder approval for two special resolutions: a name change to Aanjaay Industries Limited and an expansion of the Memorandum of Association's Main Objects Clause with twelve new sub-clauses spanning drones, defence, AI, electric vehicles, renewable energy, steel, healthcare, and agro industries. The Registrar of Companies has already approved the proposed new name. Remote e-voting is open from May 12, 2026, at 9:00 am IST to June 10, 2026, at 5:00 pm IST, with results to be declared on or before June 12, 2026.
07May 26
Kabra Drugs Board Approves Entry Into Branded Generic Products, Targets South India First
Kabra Drugs has received board approval to enter the branded generic products segment through a phased approach with strategic partners. South India has been identified as the initial target market for this expansion. Managing Director Nanjappan Aravind has been directed to begin implementation immediately, signaling the company's intent to move swiftly on this strategic initiative.
10Apr 26
Kabra Drugs Limited Board Meeting Scheduled for April 21, 2026 to Consider Independent Director Appointment and Business Diversification
Kabra Drugs Limited has scheduled a board meeting for April 21, 2026, to consider the appointment of Ms. Monam Kapoor as Independent Director and amendments to the Memorandum of Association for business diversification. The proposed MOA changes will enable expansion into drones and defence equipment, healthcare and e-pharmacy, dairy products, AI technologies, hospitality services, and agro products manufacturing. The meeting will also address postal ballot procedures, e-voting schedules, and scrutineer appointment for transparent governance processes.
07Apr 26
Kabra Drugs Limited Submits Q4FY26 SEBI Compliance Certificate for Dematerialization Process
Kabra Drugs Limited filed its Q4FY26 compliance certificate with BSE pursuant to SEBI Regulation 74(5) for the quarter ended 31st March 2026. The certificate, issued by registrar Skyline Financial Services Pvt Ltd, confirms proper dematerialization procedures including securities listing verification and timely certificate processing within regulatory timeframes. The submission demonstrates standard regulatory compliance in securities management.
07Mar 26
Kabra Drugs Limited Receives Approval for Name Change to Aanjaay Industries Limited and Announces Strategic Defence Partnership with Indonesian Company
Kabra Drugs Limited received Ministry of Corporate Affairs approval on March 06, 2026, to change its name to Aanjaay Industries Limited, with the approval valid for 60 days. The company also announced a strategic joint venture with PT. Bhinneka Dwi Persada Indonesia for defence technology development and manufacturing, supporting the Make in India initiative. The Indonesian partner specializes in strategic defence equipment including UAVs, cargo drones, and hovercraft, holding relevant intellectual property rights in Indonesia.
06Feb 26
Kabra Drugs Limited Schedules Board Meeting for February 13, 2026 to Review Q3FY26 Financial Results
Kabra Drugs Limited has scheduled a Board of Directors meeting for February 13, 2026, at 5 PM to consider and approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025. The meeting will be held at the company's Chennai Corporate Office in compliance with SEBI Regulation 33. Trading window restrictions are in effect for promoters, directors, and designated employees until 48 hours after the results announcement.
01Jan 26
Kabra Drugs Receives Approval to Acquire Vassmaan Automotive, Plans 200 Channel Partners Nationwide
Kabra Drugs has obtained regulatory approval to acquire Vassmaan Automotive, enabling the pharmaceutical company to diversify into the automotive sector. Simultaneously, the company announced plans to establish a nationwide network of 200 channel partners to strengthen its distribution capabilities and market reach across India.
01Jan 26
Kabra Drugs Board Approves Strategic Acquisitions and Business Diversification
Kabra Drugs Limited successfully concluded its January 1, 2026 board meeting with approval of transformative strategic initiatives including the acquisition of Vassmaan Automotive PVT LTD for medical equipment and EV components manufacturing, expansion of distribution network through 200 channel partners nationwide, company name change, and MOA amendments to diversify into electric vehicle components, steel manufacturing, and solar energy sectors, with all decisions subject to shareholder approval through an upcoming EGM.
14Nov 25
Kabra Drugs Limited Reports Profit Turnaround in Q2 FY2026
Kabra Drugs Limited announced financial results for Q2 FY2026, reporting a revenue of ₹1,976.40 lakhs and a net profit of ₹183.68 lakhs. This marks a significant turnaround from the previous quarter's loss. The company's basic earnings per share for the quarter was ₹0.77. The Board of Directors approved these unaudited financial statements on November 13, 2025. The company also disclosed its Board composition and reconstituted various committees as part of its corporate governance practices.
24Sept 25
Kabra Drugs to Finalize Acquisition of AMR Pharma India in Upcoming Board Meeting
Kabra Drugs Limited has scheduled a board meeting for October 8, 2025, to discuss key strategic moves. The agenda includes approving the Share Purchase Agreement for acquiring AMR PHARMA INDIA PRIVATE LIMITED, expanding the board with new technical personnel, and authorizing steps to execute the acquisition transaction. This meeting signals potential growth and enhanced expertise for the pharmaceutical company.
06Aug 25
Kabra Drugs Limited Diversifies into Medical Equipment, Establishes Chennai Office
Kabra Drugs Limited's Board of Directors has approved diversification into the medical equipment and medical instruments sector. The company will establish a new office in Chennai at Cactus Corporate Coworking, Tecci Park, to support this venture. The decision was made during a board meeting on August 6, 2025, from 6:00 PM to 7:00 PM (IST). This move represents a significant expansion of Kabra Drugs' business operations beyond pharmaceuticals.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Lupin
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
1,920.00
(+0.35%)
9,239.00
(+1.98%)
5,050.00
(+1.02%)
1,191.00
(+0.15%)
1,423.50
(+0.25%)
1,938.50
(+0.47%)
2,171.50
(+0.62%)
2,382.90
(-1.43%)
1,178.00
(+0.08%)
1,645.30
(+0.51%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
